Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combi... Read More
Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'Complementary Herbal Approach to Rheumatoid Management Study (CHARMS)'. The following are the oth... Read More
Singapore, April 15 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... Read More
Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-98650... Read More
Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open-Label, Single Dose Study to Investigate the Relative Bioavailability, Safety, and... Read More
Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In... Read More
Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'Phase II Open-label Study Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasoph... Read More
Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Multi-center, Randomized, Open-label Study to Assess the Efficacy and Safety of AHB-137... Read More
Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'Evaluating the Clinical and Economic Outcomes of Adding Semaglutide to Standard of Care in Adult ... Read More
Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with In... Read More